Eton Pharmaceuticals announced that Judith “Judy” M. Matthews will become chief financial officer on June 1, 2026. Matthews joins the company as Executive Vice President, Accounting and Finance, after serving as CFO of Iterum Therapeutics and building finance teams in growth‑focused pharmaceutical and biotechnology firms for more than 25 years.
Matthews brings a track record of scaling finance operations during periods of rapid expansion. Her experience at Iterum, where she managed the transition of multiple product launches and acquisitions, aligns with Eton’s current focus on building a large rare‑disease portfolio.
James Gruber, the current CFO, will step down on May 31, 2026, and will remain in his role through that date to facilitate a smooth handover. Gruber will then enter a six‑month consulting agreement with Eton, ensuring continuity as the company integrates new assets and expands its commercial platform.
Eton’s most recent quarterly results underscored the momentum that Matthews will inherit. In Q4 2025, product sales rose 83% year‑over‑year to $21.3 million, and full‑year 2025 revenue reached $80 million, more than double the $38 million reported in 2024. The company guided for 2026 revenue above $110 million and an adjusted EBITDA margin exceeding 30%, reflecting the impact of recent launches such as DESMODA™ and the acquisition of U.S. commercialization rights to HEMANGEOL®.
Eton’s Q4 2025 non‑GAAP EPS of $0.19 beat analysts’ consensus of $0.17, a $0.02 or 12% lift, reflecting the company’s ability to generate higher revenue while keeping costs in line with expectations.
The CFO appointment is positioned to support Eton’s next growth phase. Matthews’ expertise in finance for high‑growth pharma will help the company manage the integration of acquisitions, scale its commercial operations, and maintain disciplined cost control while pursuing aggressive revenue targets across its expanding rare‑disease product line.
In a statement, CEO Sean Brynjelsen said, “We are pleased to welcome Judy to Eton and believe she will be a valuable addition as we enter our next chapter of growth. She brings deep experience leading finance in growth‑focused pharmaceutical companies.” Brynjelsen also thanked Gruber for his leadership, noting, “On behalf of the entire Company, I want to thank James for his contributions and dedication over the last four years. He provided exceptional leadership to our finance department through a period of rapid growth and numerous product integrations.” Matthews added, “Eton’s unique model and impressive execution have set it apart in the industry. I am excited to be joining the organization at such a pivotal time, and I look forward to partnering with the team on the mission to build the largest rare disease portfolio in the United States.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.